ECSP088758A - METHODS TO REDUCE PROTEIN AGLOMERATION - Google Patents

METHODS TO REDUCE PROTEIN AGLOMERATION

Info

Publication number
ECSP088758A
ECSP088758A EC2008008758A ECSP088758A ECSP088758A EC SP088758 A ECSP088758 A EC SP088758A EC 2008008758 A EC2008008758 A EC 2008008758A EC SP088758 A ECSP088758 A EC SP088758A EC SP088758 A ECSP088758 A EC SP088758A
Authority
EC
Ecuador
Prior art keywords
methods
protein
aglomeration
reduce protein
formulations
Prior art date
Application number
EC2008008758A
Other languages
Spanish (es)
Inventor
Li Li
Angela Kantor
Nicholas W Warne
Thomas Crowley
Nicholas Luksha
Erin Soley
Edie Anna Neidhardt
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38523027&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP088758(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ECSP088758A publication Critical patent/ECSP088758A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a métodos para reducir la aglomeración de una proteína o proteínas en una formulación y formulaciones de proteínas que tienen propiedades de aglomeración reducidas. Los métodos y formulaciones descritas en este documento, mantienen la actividad biológica de una proteína e incrementan la vida de anaquel de las formulaciones de proteína.The present invention relates to methods for reducing the agglomeration of a protein or proteins in a formulation and protein formulations having reduced agglomeration properties. The methods and formulations described in this document maintain the biological activity of a protein and increase the shelf life of protein formulations.

EC2008008758A 2006-03-20 2008-09-22 METHODS TO REDUCE PROTEIN AGLOMERATION ECSP088758A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US78413006P 2006-03-20 2006-03-20

Publications (1)

Publication Number Publication Date
ECSP088758A true ECSP088758A (en) 2008-10-31

Family

ID=38523027

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008758A ECSP088758A (en) 2006-03-20 2008-09-22 METHODS TO REDUCE PROTEIN AGLOMERATION

Country Status (18)

Country Link
US (1) US20080064856A1 (en)
EP (1) EP1996221A2 (en)
JP (1) JP2009530380A (en)
KR (1) KR20080108554A (en)
CN (1) CN101420972A (en)
AR (1) AR059964A1 (en)
AU (1) AU2007227408A1 (en)
BR (1) BRPI0709059A2 (en)
CA (1) CA2646934C (en)
CR (1) CR10290A (en)
EC (1) ECSP088758A (en)
IL (1) IL194123A0 (en)
MX (1) MX2008011888A (en)
NO (1) NO20083940L (en)
PE (1) PE20080121A1 (en)
RU (1) RU2008137634A (en)
TW (1) TW200806317A (en)
WO (1) WO2007109221A2 (en)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
JP5033798B2 (en) * 2005-07-02 2012-09-26 アレコー・リミテッド Stable water system containing protein
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US20080070230A1 (en) * 2006-06-12 2008-03-20 Wyeth Methods for reducing or preventing liquid-liquid phase separation in high concentration protein solutions
PE20081610A1 (en) * 2007-01-09 2008-12-09 Wyeth Corp FORMULATIONS OF ANTI-IL-13 ANTIBODIES AND USES OF THEM
WO2009079837A1 (en) * 2007-12-18 2009-07-02 Hangzhou Jiuyuan Gene Engineering Co., Ltd. A pharmaceutical formulation containing recombinant human serum albumin-interferon alpha fusion protein
PE20091174A1 (en) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd LIQUID FORMULATION WITH HIGH CONCENTRATION OF ANTIBODY CONTENT
ES2613152T3 (en) 2008-01-09 2017-05-22 Sanofi-Aventis Deutschland Gmbh New insulin derivatives with extremely delayed time / action profile
EP2113564A1 (en) 2008-05-01 2009-11-04 Arecor Limited Protein formulation
BRPI0915414A2 (en) 2008-06-20 2021-09-08 Novartis Ag METHODS FOR IDENTIFYING AN AGGREGATION PRONE REGION AND MACROMOLECULE BINDING REGION IN A PROTEIN, AS WELL AS METHODS FOR PRODUCING A PROTEIN VARIANT AND A PHARMACEUTICAL COMPOSITION.
JP6146949B2 (en) 2008-06-20 2017-06-21 ノバルティス アーゲー Immunoglobulin with reduced aggregation
JP5364310B2 (en) * 2008-07-14 2013-12-11 アルフレッサファーマ株式会社 Method for stabilizing microparticles to which reactive substances are bound, and reagent containing the microparticles
EP2328607A1 (en) 2008-07-16 2011-06-08 Arecor Limited Stable formulation of a therapeutic protein
US20110201022A1 (en) * 2008-07-30 2011-08-18 Biomarin Pharmaceutical Inc. Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase
KR20140019035A (en) * 2008-09-19 2014-02-13 에프. 호프만-라 로슈 아게 Novel antibody formulation
CR20170369A (en) 2008-10-17 2017-11-01 Sanofi Aventis Deutschland COMBINATION OF AN INSULIN AND A GLP-1 AGONIST (Divisional 2011-0188)
CN106117348A (en) 2009-06-04 2016-11-16 诺华公司 The method identifying IgG binding site
CN102596175A (en) * 2009-07-06 2012-07-18 赛诺菲-安万特德国有限公司 Aqueous insulin preparations containing methionine
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
US12203113B2 (en) 2009-07-09 2025-01-21 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US9345661B2 (en) * 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AR078161A1 (en) 2009-09-11 2011-10-19 Hoffmann La Roche VERY CONCENTRATED PHARMACEUTICAL FORMULATIONS OF AN ANTIBODY ANTI CD20. USE OF THE FORMULATION. TREATMENT METHOD
WO2011058082A1 (en) 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a glp-1 agonist and methionine
PL2498802T3 (en) 2009-11-13 2015-06-30 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist, an insulin, and methionine
AR080428A1 (en) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd FORMULATIONS STABILIZED LIQUID CONTAINERS OF ANTIBODIES
US20130039898A1 (en) 2010-02-04 2013-02-14 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereof
US9795674B2 (en) * 2010-02-26 2017-10-24 Novo Nordisk A/S Stable antibody containing compositions
CA2792965A1 (en) 2010-04-27 2011-11-03 Scil Technology Gmbh Stable aqueous mia/cd-rap formulations
WO2011147921A1 (en) 2010-05-28 2011-12-01 Novo Nordisk A/S Stable multi-dose compositions comprising an antibody and a preservative
EP2399604A1 (en) * 2010-06-25 2011-12-28 F. Hoffmann-La Roche AG Novel antibody formulation
SG187904A1 (en) 2010-08-30 2013-04-30 Sanofi Aventis Deutschland Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
SI2661253T1 (en) * 2011-01-04 2017-07-31 Archivel Farma, Sl Liposome formulation suitable for treating or preventing tuberculosis
KR102493433B1 (en) * 2011-05-02 2023-01-27 밀레니엄 파머슈티컬스 인코퍼레이티드 FORMULATION FOR ANTI-α4β7 ANTIBODY
AU2012250924B2 (en) 2011-05-02 2017-05-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
EP2750699B1 (en) 2011-08-29 2015-07-22 Sanofi-Aventis Deutschland GmbH Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US9364542B2 (en) 2011-10-28 2016-06-14 Excelse Bio, Inc. Protein formulations containing amino acids
NO2802345T3 (en) 2012-01-12 2018-08-04
BR112014025951A2 (en) 2012-04-19 2017-07-11 Opko Biologics Ltd long-acting oxyntomodulin variants and production methods
US10132736B2 (en) 2012-05-24 2018-11-20 Abbvie Inc. Methods for inspection of protein particles in a liquid beneficial agent
JP6129832B2 (en) * 2012-05-29 2017-05-17 日本ハム株式会社 Food ingredient extract and extraction method
WO2014022817A2 (en) 2012-08-03 2014-02-06 Novartis Ag Methods to identify amino acid residues involved in macromolecular binding and uses therefor
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
KR102202255B1 (en) 2012-11-20 2021-01-13 옵코 바이오로직스 리미티드 Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
KR102423377B1 (en) 2013-08-05 2022-07-25 트위스트 바이오사이언스 코포레이션 De novo synthesized gene libraries
US20150126444A1 (en) * 2013-10-21 2015-05-07 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
US20150158926A1 (en) * 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
WO2015132724A1 (en) * 2014-03-05 2015-09-11 Pfizer Inc. Improved muteins of clotting factor viii
PL3177317T3 (en) 2014-08-04 2020-07-27 Csl Limited Factor viii formulation
EP3229828B1 (en) 2014-12-12 2023-04-05 Sanofi-Aventis Deutschland GmbH Insulin glargine/lixisenatide fixed ratio formulation
AR103173A1 (en) 2014-12-22 2017-04-19 Novarits Ag PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF ANTIBODIES IL-17
US10669304B2 (en) 2015-02-04 2020-06-02 Twist Bioscience Corporation Methods and devices for de novo oligonucleic acid assembly
TWI748945B (en) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 Treatment type 2 diabetes mellitus patients
TW201705975A (en) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 Treatment of type 2 diabetes mellitus patients
US9981239B2 (en) 2015-04-21 2018-05-29 Twist Bioscience Corporation Devices and methods for oligonucleic acid library synthesis
WO2016203482A2 (en) 2015-06-19 2016-12-22 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
TWI820795B (en) * 2015-07-30 2023-11-01 美商拜奧馬林製藥公司 Use of c-type natriuretic peptide variants to treat skeletal dysplasia
CA2998169A1 (en) 2015-09-18 2017-03-23 Twist Bioscience Corporation Oligonucleic acid variant libraries and synthesis thereof
KR102794025B1 (en) 2015-09-22 2025-04-09 트위스트 바이오사이언스 코포레이션 Flexible substrates for nucleic acid synthesis
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
CA3030533A1 (en) 2016-07-11 2018-01-18 Oren HERSHKOVITZ Long-acting coagulation factor vii and methods of producing same
SG11201901563UA (en) 2016-08-22 2019-03-28 Twist Bioscience Corp De novo synthesized nucleic acid libraries
US10417457B2 (en) 2016-09-21 2019-09-17 Twist Bioscience Corporation Nucleic acid based data storage
CN110892485B (en) 2017-02-22 2024-03-22 特韦斯特生物科学公司 Nucleic acid-based data storage
GB201703063D0 (en) 2017-02-24 2017-04-12 Arecor Ltd Stabilized antibody protein solutions
US11608357B2 (en) 2018-08-28 2023-03-21 Arecor Limited Stabilized antibody protein solutions
EP3372241A1 (en) 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
EP3372242A1 (en) 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
CA3056388A1 (en) 2017-03-15 2018-09-20 Twist Bioscience Corporation Variant libraries of the immunological synapse and synthesis thereof
TWI775827B (en) * 2017-03-31 2022-09-01 日商明治製菓藥業股份有限公司 Aqueous preparation and aqueous preparation filled in syringe, antibody protein deagglutinating agent and antibody protein deagglutinating method
CN110352201A (en) 2017-04-03 2019-10-18 免疫医疗公司 The subcutaneous administration of antibody drug conjugate for cancer therapy
WO2018231864A1 (en) 2017-06-12 2018-12-20 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
IL271205B2 (en) 2017-06-12 2025-02-01 Twist Bioscience Corp Methods for seamless nucleic acid assembly
US11407837B2 (en) 2017-09-11 2022-08-09 Twist Bioscience Corporation GPCR binding proteins and synthesis thereof
KR102637566B1 (en) 2017-10-20 2024-02-16 트위스트 바이오사이언스 코포레이션 Heated nanowells for polynucleotide synthesis
JP7158015B2 (en) 2017-11-09 2022-10-21 国立研究開発法人産業技術総合研究所 Method for suppressing aggregation of polypeptide
SG11202006460SA (en) 2018-01-04 2020-08-28 Twist Bioscience Corp Dna-based digital information storage
SG11202010684YA (en) 2018-05-10 2020-11-27 Regeneron Pharma High concentration vegf receptor fusion protein containing formulations
EP3814497A4 (en) 2018-05-18 2022-03-02 Twist Bioscience Corporation POLYNUCLEOTIDES, REAGENTS, AND METHODS FOR NUCLEIC ACID HYBRIDIZATION
WO2020044204A1 (en) * 2018-08-29 2020-03-05 Glaxosmithkline Intellectual Property Development Limited Methods of preparing stable liquid therapeutic protein compositions
JP2020052012A (en) * 2018-09-28 2020-04-02 株式会社Ｌｓｉメディエンス Immunoassay reagent using insoluble carrier
CN119708086A (en) 2018-12-26 2025-03-28 特韦斯特生物科学公司 Highly accurate de novo polynucleotide synthesis
CN113785057A (en) 2019-02-26 2021-12-10 特韦斯特生物科学公司 Variant nucleic acid libraries for antibody optimization
US11492727B2 (en) * 2019-02-26 2022-11-08 Twist Bioscience Corporation Variant nucleic acid libraries for GLP1 receptor
EP4591885A2 (en) * 2019-05-01 2025-07-30 Novo Nordisk A/S Anti-il-6 antibody formulation
WO2020257612A1 (en) 2019-06-21 2020-12-24 Twist Bioscience Corporation Barcode-based nucleic acid sequence assembly
US20220227824A1 (en) * 2019-06-24 2022-07-21 The Children's Hospital Of Philadelphia Use of srrd in the inhibition of protein aggregation
AU2020300820A1 (en) 2019-07-04 2022-03-03 CSL Behring Lengnau AG A truncated von willebrand factor (vWF) for increasing the in vitro stability of coagulation factor VIII
CN114401741A (en) 2019-07-11 2022-04-26 拓维创新生物科技(香港)有限公司 Agents that interfere with thymic stromal lymphopoietin (TSLP) receptor signaling
WO2021061829A1 (en) 2019-09-23 2021-04-01 Twist Bioscience Corporation Variant nucleic acid libraries for crth2
WO2021061842A1 (en) 2019-09-23 2021-04-01 Twist Bioscience Corporation Variant nucleic acid libraries for single domain antibodies
JP7692914B2 (en) * 2020-01-03 2025-06-16 サレプタ セラピューティクス， インコーポレイテッド Methods for Analysing AAV Capsid Proteins
JP2023538669A (en) * 2020-08-24 2023-09-08 アムジェン インコーポレイテッド Pharmaceutical formulations containing BITE, bispecific antibodies, and methionine
EP4240757A2 (en) 2020-11-09 2023-09-13 Takeda Pharmaceutical Company Limited Purification of fviii from plasma using silicon oxide adsorption
CN119855620A (en) * 2022-09-16 2025-04-18 国立研究开发法人量子科学技术研究开发机构 Method for producing intermediate of radiopharmaceutical composition, and kit for purifying intermediate of radiopharmaceutical composition
CN116559444A (en) * 2023-05-24 2023-08-08 郑州安图生物工程股份有限公司 Helicobacter pylori IgM antibody magnetic particle chemiluminescence detection kit

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US6887471B1 (en) * 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
US5932214A (en) * 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
US5843707A (en) * 1992-10-23 1998-12-01 Genetics Institute, Inc. Nucleic acid encoding a novel P-selectin ligand protein
US5358708A (en) * 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
US5516964A (en) * 1994-01-21 1996-05-14 Sun Company, Inc. (R&M) Hydrocarbon isomerization using solid superacid catalysts comprising platinum metal
US5710023A (en) * 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
PT1017413E (en) * 1997-09-23 2003-02-28 Rentschler Biotech Gmbh LIQUID INTERFERENCE FORMULATIONS (BETA)
JP2000247903A (en) * 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd Long-term stabilized pharmaceutical preparation
NZ516664A (en) * 1999-07-15 2003-06-30 Inst Genetics Llc Formulations and compositions for interleukin-11
PL211886B1 (en) * 1999-10-04 2012-07-31 Novartis Vaccines & Diagnostic Stabilized liquid polypeptide-containing pharmaceutical compositions
US6495534B2 (en) * 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use
MXPA03001092A (en) * 2000-08-07 2003-09-25 Nektar Therapeutics Al Corp Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation.
US6896906B2 (en) * 2000-12-21 2005-05-24 Nektar Therapeutics Storage stable powder compositions of interleukin-4 receptor
US20030104996A1 (en) * 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
US7051050B2 (en) * 2002-03-19 2006-05-23 Netwrok Appliance, Inc. System and method for restoring a single file from a snapshot
US20040022792A1 (en) * 2002-06-17 2004-02-05 Ralph Klinke Method of stabilizing proteins at low pH
WO2004000347A1 (en) * 2002-06-21 2003-12-31 Novo Nordisk A/S Stabilised solid compositions of factor vii polypeptides
EP1599222B1 (en) * 2003-01-08 2009-03-04 Novartis Vaccines and Diagnostics, Inc. Stabilized aqueous compositions comprising tissue factor pathway inhibitor (tfpi) or tissue factor pathway inhibitor variant
BRPI0418115A (en) * 2003-12-23 2007-04-17 Pharmacia Corp stable liquid growth hormone formulation
EA010979B1 (en) * 2004-06-01 2008-12-30 Арес Трейдинг С.А. Stabilized interferon liquid formulations
BRPI0510527A (en) * 2004-06-01 2007-10-30 Ares Trading Sa protein stabilization method
UY29350A1 (en) * 2005-01-28 2006-08-31 Wyeth Corp POLYPEPTIDE STABILIZED LIQUID FORMULATIONS

Also Published As

Publication number Publication date
WO2007109221A2 (en) 2007-09-27
NO20083940L (en) 2008-10-16
RU2008137634A (en) 2010-04-27
BRPI0709059A2 (en) 2011-06-21
KR20080108554A (en) 2008-12-15
WO2007109221A3 (en) 2008-02-21
AR059964A1 (en) 2008-05-14
PE20080121A1 (en) 2008-03-05
AU2007227408A1 (en) 2007-09-27
WO2007109221A9 (en) 2007-12-06
JP2009530380A (en) 2009-08-27
MX2008011888A (en) 2008-09-29
CA2646934C (en) 2014-09-23
IL194123A0 (en) 2011-08-01
CN101420972A (en) 2009-04-29
CA2646934A1 (en) 2007-09-27
CR10290A (en) 2008-11-26
EP1996221A2 (en) 2008-12-03
TW200806317A (en) 2008-02-01
US20080064856A1 (en) 2008-03-13

Similar Documents

Publication Publication Date Title
ECSP088758A (en) METHODS TO REDUCE PROTEIN AGLOMERATION
ECSP099514A (en) ACTIVTA-ACTRII ANTAGONISTS AND USES TO INCREASE THE LEVELS OF RED BLOODS
CR20170130A (en) FORMULATIONS OF LIOFILIZED THERAPEUTIC PEPTIBODIES
GT200600316A (en) SALTS OF 4-METHYL-N- (3- (4-METHYL-IMIDAZOL-1-ILO) -5-TRIFLUOROMETILO-PHENYL) -3- (4-PIRIDINA-3-ILO-PIRIMIDINA-2-ILOAMINO) - BENZAMIDA.
DOP2006000179A (en) 7-AZA-SUBSTITUTED INDAZOLS, COMPOSITIONS THAT CONTAIN THEM, MANUFACTURING AND USE PROCEDURE
ECSP088440A (en) IMIDAZOPIRAZINS AS INHIBITORS OF PROTEINQUINASA
ECSP088350A (en) PIRAZOLOPIRIMIDINAS AS INHIBITORS OF PROTEIN KINASES
ECSP088262A (en) ALBUMIN FUSION PROTEINS
UY29196A1 (en) SEED OIL COMPOSITIONS
ATE464902T1 (en) STABLE PHARMACEUTICAL PREPARATIONS OF MONTELUKAST SODIUM
CY1113199T1 (en) STABILIZED GLUCOSEREMPRODUCTION COMPOSITIONS
EA200802184A1 (en) PHARMACEUTICAL COMPOSITIONS WITH DPP IV INHIBITORS
MX354100B (en) Protein formulations and methods of making same.
ECSP10010548A (en) COMPOSITIONS AND METHODS OF PREPARATION AND USE OF THE SAME
CO6300826A2 (en) METHODS AND COMPOSITIONS THAT USE KLOTHO-FGF FUSION POLYPEPTIDES
BRPI0514340A (en) stabilization formulations
CR9246A (en) THERAPEUTIC FORMULATIONS OF THE KERATINOCIT GROWTH FACTOR
CR20110608A (en) DERIVATIVES OF 1H-IMIDAZO- [4,5-C] -QUINOLINONA
BR112015022210A8 (en) antibody formulations
BRPI0606687A2 (en) nutraceutical compositions
ATE489371T1 (en) BENZAMIDE GLUCOCINASE ACTIVATORS
CY1117174T1 (en) USE OF 24-norUDCA FOR TREATMENT OF US CHOLOGICAL DISEASES
AR113492A2 (en) RECOMBINANT FURIN FREE OF SUBSTANTIALLY ANIMAL PROTEINS AND METHODS TO PRODUCE IT
CY1112620T1 (en) COMPOSITIONS WHICH INCLUDE MYELINE BASIC PROTEIN PATIENTS AND THEIR MEDICAL USES
MX383505B (en) HUMAN ENZYME-MEDIATED CYSTINE REMOVAL.